Publications by authors named "P Arenberger"

Claim this Profile
H
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study.
Andrew Blauvelt, Petr Arenberger, Maxwell B Sauder, Megan Couvillion, Roman G Rubio

J Am Acad Dermatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Messages for ultraviolet-radiation protection to fair-skinned populations.
Lieve Brochez, Claus Garbe, Teresa Amaral, Petr Arenberger, Violeta Astratinei

J Eur Acad Dermatol Venereol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Biomarkers for Anti-PD-1 Monoclonal Antibodies in the First Line Treatment of Advanced Melanoma.
Marek Pásek, Emanuel Marques, Vojtěch Tretera, Petr Arenberger, Monika Arenbergerová

Int J Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, Helen Gogas, Ana M Arance, Petr Arenberger

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.
Martina Kojanova, Daniela Pejrilova, Jorga Fialova, Petra Cetkovska, Spyridon Gkalpakiotis, Petr Arenberger

Int J Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis